<sentence id="0">Binding of RUNX1 and RUNX3 proteins to the predicted binding sites in the FOXP3 promoter .</sentence>
<sentence id="1">( A ) Mutated and wild-type oligonucleotides are shown .</sentence>
<sentence id="2">The predicted RUNX binding sites are accentuated ( boxed and in green letters ) and stars mark mutations introduced into the binding site of the control oligonucleotides .</sentence>
<sentence id="3">Nuclear extracts from HEK293T cells were incubated with biotinylated oligonucleotides .</sentence>
<sentence id="4">The precipitated oligonucleotide==-==transcription factor complexes were separated by SDS-PAGE and identified by Western blotting with anti-RUNX1 and anti-RUNX3 antibodies .</sentence>
<sentence id="5">A mixture of all three oligonucleotides with the predicted binding sites or with the inserted mutation into the predicted sites was used .</sentence>
<sentence id="6">Data shown are one representative of three independent experiments with similar results .</sentence>
<sentence id="7">( B ) Promoter enzyme immunoassay using wild-type and mutated oligonucleotides within the FOXP3 promoter .</sentence>
<sentence id="8">Bars show mean = = +/- = = SE of three independent experiments .</sentence>
<sentence id="9">( C ) Chromatin immunoprecipitation assay results show binding of RUNX1 and RUNX3 complexes containing CBF==beta = = to the human FOXP3 promoter in naive CD4+ T cells that were cultured with IL-2 together with anti-CD2/3/28 and TGF-==beta = = .</sentence>
<sentence id="10">There was <scope type="neg" id="0"><cue type="neg" id="0">no</cue> change in site occupancy in all immunoprecipitations</scope> when IGX1A negative control primers were used .</sentence>
<sentence id="11">The results are normalized to input and isotype control antibody .</sentence>
<sentence id="12">Bars show mean = = +/- = = SE of three independent experiments .</sentence>
<sentence id="13">Statistical differences were verified by the paired Student 's t test .</sentence>
<sentence id="14">* , P < 0.05</sentence>